HAI Solutions Gains FDA Approval for Cutting-Edge QIKCAP System
HAI Solutions, a notable innovator in the realm of ultraviolet (UVC) microbial reduction medical devices, recently marked an important milestone with the granting of De Novo classification by the U.S. Food and Drug Administration (FDA) for their QIKCAP System. This groundbreaking device is the first of its kind, establishing a new category of Class II medical devices focused on ultraviolet light-based microbial reduction.
The Technology Behind QIKCAP
The QIKCAP System consists of the QIKCAP Device and a single-use QIKCAP Cap. Designed to enhance manual disinfection procedures for needle-free luer connectors in intravenous applications, this innovative system offers a quick and efficient solution. The QIKCAP Device is adept at delivering powerful, targeted UVC irradiation directly to the connector septum, achieving notable microbial reduction in as little as 10 seconds. Furthermore, the QIKCAP Cap functions as a protective barrier, safeguarding the connector from environmental contaminants for up to seven days when not in use.
HAI Solutions: Leading the Way in UVC Microbial Reduction
This achievement positions HAI Solutions as a leader in the field of UVC microbial reduction medical devices. The company has a growing portfolio that includes a partnership with Intellego Technologies aimed at developing an innovative chromatic dosimeter tailored for UVC applications. HAI Solutions advocates for stringent FDA regulations concerning UVC healthcare devices, underscoring the necessity of rigorous standards to ensure patient safety and device efficacy.
A Remarkable Achievement for HAI Solutions
Nick Perrenoud, the CEO of HAI Solutions, expressed his pride in this significant accomplishment: "This De Novo Grant represents a tremendous achievement for our team at HAI Solutions. We are thrilled to introduce this cutting-edge technology into the market, addressing a vital need for better maintenance and protection of IV connectors."
The Validation Process by the FDA
Throughout the De Novo process, HAI Solutions collaborated extensively with the FDA, adhering to comprehensive general and special controls. These controls necessitated thorough performance testing under the most challenging conditions. These stringent measures ensure that the QIKCAP Device is reliable and safe for use in clinical environments. During testing, the combination of a 3.15% CHG/70% IPA wipe applied for five seconds, alongside the use of the QIKCAP Device, resulted in an impressive four-log reduction in several pathogens, including Staphylococcus aureus, Klebsiella pneumoniae, Staphylococcus epidermidis, and Enterobacter cloacae. However, the device has not demonstrated a significant reduction in fungal organisms, and a direct link to clinical infection-related outcomes has yet to be established.
About HAI Solutions
Headquartered in Carlsbad, California, HAI Solutions is at the forefront of delivering advanced intravenous therapy solutions designed to mitigate IV contamination in critical settings such as operating rooms, intensive care units, and emergency departments. Their commitment to innovation ensures ongoing improvements in patient care and safety. For more information, please visit www.HAI-Solutions.com.
Frequently Asked Questions
What is the QIKCAP System?
The QIKCAP System is a UVC microbial reduction device designed for needle-free luer connectors in intravenous applications, improving disinfection protocols.
What was the significance of the FDA De Novo classification?
The De Novo classification establishes the QIKCAP as a first-of-its-kind device in a new category for medical devices focused on UVC microbial reduction.
How does the QIKCAP Device function?
The device delivers targeted UVC irradiation to the connector septum for rapid microbial reduction within seconds, enhancing safety in iv therapy.
What safety measures did HAI Solutions implement during testing?
HAI Solutions worked with the FDA to ensure rigorous testing conditions to validate the safety and performance of the QIKCAP Device in clinical environments.
What future advancements can we expect from HAI Solutions?
HAI Solutions aims to expand its portfolio with new technologies focused on improving IV safety and minimizing contamination risks in healthcare settings.
